Consenso uruguayo de manejo del infarto agudo de ... - SciELO

et al. Effects of long-term treatment with angiotensin-converting-enzyme
inhibitors in the presence or absence of aspirin: a systematic review. Lancet
2002; 360: 1037-43.
51. Sigurdsson A, Swedberg K. Left ventricular remodelling,
neurohormonal activation and early treatment with enalapril (CONSENSUS
II) following myocardial infarction. Eur Heart J 1994; 15(Suppl B): 14-9;
discussion 26.
52. Pfeffer MA, Braunwald E, MoyéLA, Basta L, et al, for the SAVE
Investigators. Effect of captopril on mortality and morbidity in patients
with left ventricular dysfunction after myocardial infarction: results of the
survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-77.
53. The Acute Infarction Ramipril Efficacy (AIRE) Study
Investigators. Effect of ramipril on mortality and morbidity of survivors of
acute myocardial nfarction with clinical evidence of heart failure. Lancet
1993; 342: 821-8.
54. Køber L, Torp-Pedersen C, Carlsen JE, et al, for the Trandolapril
Cardiac Evaluation (TRACE) Study Group. A clinical trial of the
angiotensin-converting-enzyme inhibitor trandolapril in patients with left
ventricular dysfunction after myocardial infarction. N Engl J Med 1995;
333: 1670-6.
55. Johnstone D, Limacher M, Rousseau M, Liang CS, Ekelund L,
Herman M, et al. Clinical characteristics of patients in studies of left
ventricular dysfunction(SOLVD). Am J Coll Cardiol 1992; 70: 894-900.
56. Effect of enalapril on mortality and the development of heart failure in
asymptomatic patients with reduced left ventricular ejection fractions. The
SOLVD Investigattors. N Engl J Med 1992; 327: 685-91.
57. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC,
Kowey PR, et al. Effects of captopril on ischemic events after myocardial
infarction: Results of the Survival and Ventricular Enlargement trial.
Circulation 1994; 90: 1731-8.
58. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the
Heart Outcomes Prevention Evaluation Study Investigators. Effects of
an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients. N Engl J Med 2000; 342: 145-53.
59. Fox KM for the EURopean trial On reduction of cardiac events
with Perindopril in stable coronary Artery disease Investigators.
Efficacy of perindopril in reduction of cardiovascular events among patients
with stable coronary artery disease: randomised, double-blind, placebocontrolled,
multicentre trial (the EUROPAstudy). Lancet 2003; 362: 782-8.
60. Dickstein K, Kjekshus J, for the OPTIMAAL Steering Committee
of the OPTIMAAL Study Group. Effects of losartan and captopril on
mortality and morbidity in high-risk patients after acute myocardial
infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial
Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-
60.